OPTIC TRIAL OF ADVM-022 IN WET AMD


Associated tags: OPTIC, IVT, Standard of care, Retina, Vaccine, NAMD, Adverum Biotechnologies, Safety, Macular degeneration, AMD, Patient, Severe cognitive impairment, Neovascularization, Incidence, Research, Prevalence, Pharmaceutical industry, Injection, VEGF, Gene therapy of the human retina

Adverum Biotechnologies Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Quality of life, GLOBE, Private Securities Litigation Reform Act, NAMD, Prevalence, Investment, Gene therapy of the human retina, Annual general meeting, Food, Nasdaq, Research, Society, Incidence, Injection, Technology, IRF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neovascularization, Severe cognitive impairment, SEC, NASDAQ, American Academy, Patient, AMD, Macular degeneration, Safety, Compliance, U.S. Securities and Exchange Commission, Caregiver, OPTIC, VEGF, Home After Three Months Away, Retina, Standard of care, European Medicines Agency, Drug discovery, SRF, IVT, Pharmaceutical industry, Birth control, Vaccine, Adverum Biotechnologies

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the third quarter ended September 30, 2022.

Key Points: 
  • In July 2022, Adverum completed an Investigational New Drug amendment with the U.S. Food and Drug Administration to advance a Phase 2 trial of Ixo-vec in wet AMD.
  • Stock-based compensation expense included in research and development expenses was $1.4 million for the third quarter of 2022.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the third quarter of 2022.
  • Additional risks and uncertainties facing Adverum are set forth under the caption Risk Factors and elsewhere in Adverums Securities and Exchange Commission (SEC) filings and reports, including Adverums Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 11, 2022.

Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)

Retrieved on: 
Friday, November 4, 2022
Patient, Severe cognitive impairment, Gene therapy of the human retina, VEGF, AMD, Private Securities Litigation Reform Act, Research, Compliance, Maintenance, CST, IVT, GLOBE, Steroid, Safety, Incidence, OPTIC, Retina, NAMD, Macular degeneration, Nasdaq, Standard of care, Physician, U.S. Securities and Exchange Commission, NASDAQ, Prevalence, Injection, Inflammation, Wills Eye Hospital, Technology, SEC, Neovascularization, Birth control, Pharmaceutical industry, Vaccine, Adverum Biotechnologies

REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced long-term follow-up data from the OPTIC study treating wet age-related macular degeneration (wet AMD) during The Retina Society Annual Meeting in Pasadena, California. New data presented include final two-year safety and efficacy assessment of Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022), including reduction in annualized anti-VEGF injections, clinically relevant aflibercept protein levels and maintenance to improvement of mean best-corrected visual acuity (BCVA) and central subfield thickness (CST). OPTIC study participants could enroll in an extension study for an additional three years for a total of five years of follow-up.

Key Points: 
  • OPTIC study participants could enroll in an extension study for an additional three years for a total of five years of follow-up.
  • We are pleased to present our final two-year analysis from our OPTIC trial of Ixo-vec for the treatment of wet AMD.
  • All 2E11 participants were inflammation free and did not require steroids to treat inflammation at the end of the study.
  • Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD.

Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting

Retrieved on: 
Thursday, October 27, 2022
NASDAQ, Prevalence, Publication, Safety, Nasdaq, Patient, Macular degeneration, OPTIC, Neovascularization, Compliance, NAMD, Retina, Severe cognitive impairment, Research, GLOBE, Standard of care, IVT, Incidence, AMD, Pharmaceutical industry, Vaccine, Adverum Biotechnologies

Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD.

Key Points: 
  • Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD.
  • The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age.
  • AMD is projected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.
  • ADVM-022, ixoberogene soroparvovec (Ixo-vec), is Adverums clinical-stage gene therapy product candidate being developed for the treatment of wet AMD.